24 May 2013
Keywords: erbitux, fails, ph, iii, pancreatic, cancer, trial
Article | 16 April 2007
New York, USA-based firms ImClone Systems and Bristol-Myers Squibb say that a Phase III study of the anticancer drug Erbitux ( ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
16 April 2007
9 April 2007
23 April 2007
© 2013 thepharmaletter.com